CRT 23: vFFr vs FFR Guided Revascularization in Patients with Coronary Artery Disease: The FAST III Trial

Published: 17 Mar 2023

  • Views:

    Views Icon 42
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

CRT 23 - In this short interview from CRT's 2023 Scientific Sessions, we are joined by Dr Joost Daemen (Thoraxcenter, Erasmus University Medical Center, NL) to outline the FAST III Trial, sponsored by the European Cardiovascular Research Institute. In this study, over 2000 patients were randomized in a 1:1 manner, to vFFR or FFR guided revascularization for the treatment of coronary artery disease. Patients are followed up to 12 months, at which point, the primary endpoints of all-cause death, myocardial infarction and revascularization are analysed. 


  1. What was the rationale behind this study?
  2. What was the patient population, current enrollment status and study design?
  3. What is the potential impact of the results of this trial?
  4. What are the next steps for FAST III?

Recorded remotely from Rotterdam, 2023. 

Editor: Jordan Rance

Videography: Dan Brent


You must be to comment. If you are not registered, you can register here.